严重烧伤患者入院时PenKid水平与预后相关
这项两中心前瞻性观察研究纳入113例TBSA>15%的严重烧伤成人患者,发现入院时血浆PenKid浓度在非存活者和AKI患者中显著更高,且PenKid在血清肌酐和SOFA评分基础上对90天死亡率具有额外预测价值。
要点
- 入院血浆PenKid升高与严重烧伤患者90天死亡风险增加相关。
- PenKid在血清肌酐和SOFA评分基础上可额外预测90天死亡率。
- 亚临床AKI患者(无AKI但PenKid升高)生存率介于无AKI与AKI之间。
核心结论
- 入院时血浆PenKid浓度与严重烧伤患者死亡风险增加相关。
- PenKid在血清肌酐和SOFA评分基础上对预测90天死亡率具有额外预后价值。
研究设计与样本
- 前瞻性观察研究,在两个中心纳入113例连续严重烧伤成人患者。
- 纳入标准为TBSA烧伤>15%、烧伤至ICU入院<72小时且入院时采集血浆样本。
- 主要终点为90天死亡率,次要终点为AKI及90天死亡和/或AKI的复合终点。
主要发现
- 患者中位年龄48岁(IQR 33-64),中位烧伤TBSA为35%(IQR 25-53),90天死亡率为31.9%。
- 31%的患者发生AKI,41.6%的患者达到复合终点。
- 无AKI、亚AKI和AKI患者的生存率分别为90.0%(95%CI 82.7-97.9)、66.7%(95%CI 48.1-92.4)和31.4%(95%CI 19.3-51.3),p<0.001。
- 非存活者血浆PenKid浓度显著高于存活者(86.9 pmol/L [IQR 53.3-166.1] vs 52.9 pmol/L [IQR 37.1-70.7],p=0.0001)。
- AKI患者血浆PenKid浓度显著高于非AKI患者(86.4 pmol/L [IQR 56.5-153.4] vs 52.5 pmol/L [IQR 35.5-71.2],p<0.001)。
关键数值与推荐
- PenKid联合血清肌酐预测90天死亡的c-index为0.738,优于血清肌酐单独的0.707(p=0.024)。
- PenKid联合SOFA评分预测90天死亡的c-index为0.787,优于SOFA单独的0.752(p<0.001)。
- 亚临床AKI定义为无AKI但PenKid升高。
临床怎么用
- 对严重烧伤患者入院时检测血浆PenKid可能有助于早期风险分层。
- PenKid可作为血清肌酐和SOFA评分之外的补充预后指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proenkephalin A 119-159 (penKid) has been proposed as a sensitive biomarker of renal function. This study evaluated the association of concentrations of plasma penKid with death and risk of acute kidney injury (AKI) in severely ill burn patients. METHODS: A prospective observational study in two centers with severely ill adult burn patients was conducted. The inclusion criteria were total body surface area (TBSA) burns >15%, with burn injury occurring <72 h before intensive care unit (ICU) admission and plasma sample taken at admission. The primary endpoint was 90-day mortality. The secondary endpoints were AKI and a combined endpoint of 90-day mortality and/or AKI. Mortality was also evaluated in the sub-group of patients with sub-clinical AKI, defined as a patient without AKI but with elevated penKid. RESULTS: A total of 113 consecutive patients were enrolled. The median age was 48 years (Interquartile range [IQR] 33-64), the median burn TBSA was 35% (IQR 25-53), and 90-day mortality was 31.9%. Thirty-one percent of the patients had AKI, and 41.6% of patients had the combined endpoint. There was a stepwise decrease in survival from patients without AKI, sub-AKI, and with AKI (survival rate 90.0% [95% CI 82.7-97.9], 66.7% [95% CI 48.1-92.4], and 31.4% [95% CI 19.3-51.3], respectively, p < 0.001). Plasma penKid concentration was significantly higher in non-survivors compared to survivors (86.9 pmol/L [IQR 53.3-166.1] versus 52.9 pmol/L [IQR 37.1-70.7]; p = 0.0001) and in patients with AKI compared to patients without AKI (86.4 pmol/L [IQR 56.5-153.4] versus 52.5 pmol/L [IQR 35.5-71.2]; p < 0.001). Penkid provided added value on top of serum creatinine (Screat) and Sepsis Related Organ Failure Assessment (SOFA) scores to predict 90-day mortality (combined c-index of 0.738 versus 0.707; p = 0.024 and 0.787 versus 0.752; p < 0.001). CONCLUSIONS: Plasma penKid concentration at admission was associated with an increased risk of death in burn patients. PenKid has additional prognostic value on top of Screat and SOFA to predict 90-day mortality.
引用
- Dépret F, Polina A, Amzallag J, et al. PenKid measurement at admission is associated with outcome in severely ill burn patients. Burns. 2020. PMID: 31987659. doi:10.1016/j.burns.2020.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。